Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185 |
Resumo: | Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates. |
id |
RCAP_acb9afd87727bb8c5292af010fcae4f5 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/17185 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da EuropaParagangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da EuropaCarotid Body TumorCranial Nerve NeoplasmsExtra-Adrenal ParagangliomaHead and Neck NeoplasmsParagangliomaNeoplasias de Cabeça e PescoçoNeoplasias dos Nervos CranianosParagangliomaParaganglioma ExtrassuprarrenalTumor do Corpo CarotídeoIntroduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates.Introdução: Os paragangliomas apresentam frequentemente um comportamento benigno e um crescimento indolente. Apesar disso, são localmente invasivos, podendo causar morbilidade significativa. O objetivo deste trabalho foi descrever as manifestações clínicas, atividade secretora, estudos genéticos e imagiológicos, modalidades terapêuticas, complicações e sobrevivência dos doentes com paragangliomas da cabeça e pescoço.Material e Métodos: Estudo retrospetivo dos doentes com paragangliomas da cabeça e pescoço observados num centro hospitalar terciário entre 1997 e 2020.Resultados: Foram incluídos no estudo 73 doentes, englobando 89 paragangliomas. Quarenta e oito doentes (65,8%) eram do sexo feminino e 15 (20,5%) apresentavam múltiplos focos tumorais (10 por multicentricidade e cinco por doença maligna disseminada). Foram incluídos 40 paragangliomas do osso temporal (44,9%), 24 tumores do corpo carotídeo (27%), 22 vagais (24,7%), dois laríngeos (2,2%) e um nasossinusal (1,1%). A secreção excessiva de catecolaminas foi detetada em 11 doentes (15,1%). Sessenta e quatro doentes (87,7%) foram alvo de teste genético. Desses, 24 (37,5%) exibiram mutações patogénicas do complexo succinato desidrogenase. Dos doentes com doença primária, 45 (66,2%; 55 tumores) foram submetidos a tratamento cirúrgico, 20 (29,4%; 23 tumores) a radioterapia e três (4,4%) ficaram sob vigilância. Aos cinco anos, a sobrevida global foi de 94,9% e a sobrevida livre de doença foi de 31,9%.Conclusão: Os paragangliomas da cabeça e pescoço são tumores raros, de crescimento lento, mas localmente agressivos que resultam em elevadas taxas de morbilidade, mas baixas taxas de mortalidade.Ordem dos Médicos2022-03-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185oai:ojs.www.actamedicaportuguesa.com:article/17185Acta Médica Portuguesa; Vol. 35 No. 11 (2022): November; 789-797Acta Médica Portuguesa; Vol. 35 N.º 11 (2022): Novembro; 789-7971646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185/6577Direitos de Autor (c) 2022 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessCastelhano, LuísCorreia, FilipeDonato, SaraFerreira, LígiaMontalvão, PedroMagalhães, Miguel2022-12-20T11:08:00Zoai:ojs.www.actamedicaportuguesa.com:article/17185Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:20:54.779615Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
title |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
spellingShingle |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa Castelhano, Luís Carotid Body Tumor Cranial Nerve Neoplasms Extra-Adrenal Paraganglioma Head and Neck Neoplasms Paraganglioma Neoplasias de Cabeça e Pescoço Neoplasias dos Nervos Cranianos Paraganglioma Paraganglioma Extrassuprarrenal Tumor do Corpo Carotídeo |
title_short |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
title_full |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
title_fullStr |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
title_full_unstemmed |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
title_sort |
Paragangliomas da Cabeça e Pescoço: A Experiência de um Centro Oncológico do Sul da Europa |
author |
Castelhano, Luís |
author_facet |
Castelhano, Luís Correia, Filipe Donato, Sara Ferreira, Lígia Montalvão, Pedro Magalhães, Miguel |
author_role |
author |
author2 |
Correia, Filipe Donato, Sara Ferreira, Lígia Montalvão, Pedro Magalhães, Miguel |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Castelhano, Luís Correia, Filipe Donato, Sara Ferreira, Lígia Montalvão, Pedro Magalhães, Miguel |
dc.subject.por.fl_str_mv |
Carotid Body Tumor Cranial Nerve Neoplasms Extra-Adrenal Paraganglioma Head and Neck Neoplasms Paraganglioma Neoplasias de Cabeça e Pescoço Neoplasias dos Nervos Cranianos Paraganglioma Paraganglioma Extrassuprarrenal Tumor do Corpo Carotídeo |
topic |
Carotid Body Tumor Cranial Nerve Neoplasms Extra-Adrenal Paraganglioma Head and Neck Neoplasms Paraganglioma Neoplasias de Cabeça e Pescoço Neoplasias dos Nervos Cranianos Paraganglioma Paraganglioma Extrassuprarrenal Tumor do Corpo Carotídeo |
description |
Introduction: Paragangliomas are usually benign slow-growing tumors, but they are locally invasive and can cause significant morbidity. The aim of this study was to characterize the presenting symptoms, secretory status, genetics, imaging features, treatment modalities, post-treatment complications and survival of patients with head and neck paragangliomas treated at a single institution.Material and Methods: We retrospectively reviewed the clinical records of patients managed at our center between 1997 and 2020.Results: Seventy-three patients were included in the study, encompassing 89 head and neck paragangliomas. Forty-eight patients (65.8%) were female and 15 (20.5%) had multiple tumor sites (including 10 patients with multicentric benign paragangliomas and five with disseminated malignant disease). Regarding location, our series encompassed 40 temporal bone paragangliomas (44.9%), 24 carotid body paragangliomas (27%), 22 vagal paragangliomas (24.7%), two laryngeal paragangliomas (2.2%) and one sinonasal paraganglioma (1.1%). Excessive catecholamine secretion was detected in 11 patients (15.1%). Sixty-four patients (87.7%) underwent genetic testing. Of those, 24 (37.5%) exhibited pathogenic succinate dehydrogenase complex germline mutations. Regarding patients who presented with untreated disease, 45 patients (66.2%), encompassing 55 tumors, underwent surgery as primary treatment modality, 20 (29.4%; 23 tumors) were initially treated with radiotherapy and three patients (4.4%, encompassing three solitary tumors) were kept solely under watchful waiting. Five-year overall survival was 94.9% and disease-free survival was 31.9%.Conclusion: Head and neck paragangliomas are rare, slow-growing but locally aggressive tumors resulting in high morbidity but low mortality rates. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-03-15 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185 oai:ojs.www.actamedicaportuguesa.com:article/17185 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/17185 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/17185/6577 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2022 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2022 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 35 No. 11 (2022): November; 789-797 Acta Médica Portuguesa; Vol. 35 N.º 11 (2022): Novembro; 789-797 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130656615170048 |